Recent Analysts’ Ratings Updates for Cogent Biosciences (COGT)

Cogent Biosciences (NASDAQ: COGT) recently received a number of ratings updates from brokerages and research firms:

• 12/22/2025 – Cogent Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/20/2025 – Cogent Biosciences was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/19/2025 – Cogent Biosciences had its price target raised by analysts at JPMorgan Chase & Co. to $67.00. They now have an “overweight” rating on the stock.
• 12/15/2025 – Cogent Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Cogent Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Cogent Biosciences had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $48.00 price target on the stock.
• 12/8/2025 – Cogent Biosciences had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 11/24/2025 – Cogent Biosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Cogent Biosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Cogent Biosciences had its price target raised by analysts at HC Wainwright from $21.00 to $50.00. They now have a “buy” rating on the stock.
• 11/11/2025 – Cogent Biosciences had its price target raised by analysts at Robert W. Baird from $14.00 to $34.00. They now have a “neutral” rating on the stock.
• 11/10/2025 – Cogent Biosciences had its price target raised by analysts at Leerink Partners from $18.00 to $50.00. They now have an “outperform” rating on the stock.
• 11/10/2025 – Cogent Biosciences was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating. They now have a $40.00 price target on the stock.
• 11/10/2025 – Cogent Biosciences was upgraded by analysts at Wedbush from a “neutral” rating to an “outperform” rating. They now have a $38.00 price target on the stock.
• 11/4/2025 – Cogent Biosciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.